nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—muscle cancer	0.693	1	CtDrD
Temsirolimus—CYP3A7—Vincristine—muscle cancer	0.0278	0.147	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0278	0.147	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—muscle cancer	0.022	0.117	CbGbCtD
Temsirolimus—CYP3A5—Vincristine—muscle cancer	0.0209	0.11	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—muscle cancer	0.0191	0.101	CbGbCtD
Temsirolimus—ABCB1—Vincristine—muscle cancer	0.0136	0.0718	CbGbCtD
Temsirolimus—ABCB1—Etoposide—muscle cancer	0.0124	0.0658	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—muscle cancer	0.00848	0.0449	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—muscle cancer	0.00822	0.0435	CbGbCtD
Temsirolimus—CYP3A4—Vincristine—muscle cancer	0.00813	0.043	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—muscle cancer	0.00799	0.0423	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—muscle cancer	0.00745	0.0394	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—muscle cancer	0.00508	0.0269	CbGbCtD
Temsirolimus—MTOR—hindlimb—muscle cancer	0.00404	0.192	CbGeAlD
Temsirolimus—MTOR—appendage—muscle cancer	0.00347	0.165	CbGeAlD
Temsirolimus—FKBP1A—TGF-beta Receptor Signaling—TFE3—muscle cancer	0.00121	0.0761	CbGpPWpGaD
Temsirolimus—MTOR—embryo—muscle cancer	0.00115	0.0548	CbGeAlD
Temsirolimus—MTOR—smooth muscle tissue—muscle cancer	0.000905	0.0431	CbGeAlD
Temsirolimus—MTOR—renal system—muscle cancer	0.000871	0.0415	CbGeAlD
Temsirolimus—FKBP1A—smooth muscle tissue—muscle cancer	0.000814	0.0387	CbGeAlD
Temsirolimus—FKBP1A—renal system—muscle cancer	0.000784	0.0373	CbGeAlD
Temsirolimus—FKBP1A—cardiac atrium—muscle cancer	0.000702	0.0334	CbGeAlD
Temsirolimus—MTOR—tendon—muscle cancer	0.00068	0.0324	CbGeAlD
Temsirolimus—MTOR—bone marrow—muscle cancer	0.000659	0.0314	CbGeAlD
Temsirolimus—MTOR—vagina—muscle cancer	0.000631	0.03	CbGeAlD
Temsirolimus—FKBP1A—tendon—muscle cancer	0.000612	0.0291	CbGeAlD
Temsirolimus—FKBP1A—bone marrow—muscle cancer	0.000593	0.0282	CbGeAlD
Temsirolimus—MTOR—head—muscle cancer	0.000583	0.0277	CbGeAlD
Temsirolimus—FKBP1A—vagina—muscle cancer	0.000568	0.027	CbGeAlD
Temsirolimus—MTOR—testis—muscle cancer	0.000563	0.0268	CbGeAlD
Temsirolimus—FKBP1A—head—muscle cancer	0.000524	0.025	CbGeAlD
Temsirolimus—FKBP1A—testis—muscle cancer	0.000507	0.0241	CbGeAlD
Temsirolimus—MTOR—Class I PI3K signaling events mediated by Akt—FOXO4—muscle cancer	0.000361	0.0227	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—KIDINS220—muscle cancer	0.000344	0.0216	CbGpPWpGaD
Temsirolimus—CYP3A5—renal system—muscle cancer	0.000341	0.0162	CbGeAlD
Temsirolimus—MTOR—FSH signaling pathway—FOXO1—muscle cancer	0.000328	0.0206	CbGpPWpGaD
Temsirolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—PTGS2—muscle cancer	0.000318	0.02	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—WT1—muscle cancer	0.00029	0.0182	CbGpPWpGaD
Temsirolimus—MTOR—Class I PI3K signaling events mediated by Akt—FOXO1—muscle cancer	0.000266	0.0167	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIDINS220—muscle cancer	0.000258	0.0162	CbGpPWpGaD
Temsirolimus—CYP3A4—renal system—muscle cancer	0.000256	0.0122	CbGeAlD
Temsirolimus—MTOR—IL4-mediated signaling events—HMGA1—muscle cancer	0.000254	0.016	CbGpPWpGaD
Temsirolimus—CYP2D6—renal system—muscle cancer	0.000252	0.012	CbGeAlD
Temsirolimus—CYP3A5—vagina—muscle cancer	0.000247	0.0118	CbGeAlD
Temsirolimus—ABCB1—embryo—muscle cancer	0.00024	0.0114	CbGeAlD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000226	0.0142	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KIDINS220—muscle cancer	0.000198	0.0125	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—FOXO1—muscle cancer	0.000188	0.0118	CbGpPWpGaD
Temsirolimus—ABCB1—renal system—muscle cancer	0.000181	0.00863	CbGeAlD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO4—muscle cancer	0.000176	0.011	CbGpPWpGaD
Temsirolimus—Fluid retention—Doxorubicin—muscle cancer	0.000175	0.00217	CcSEcCtD
Temsirolimus—Urethral disorder—Etoposide—muscle cancer	0.000175	0.00216	CcSEcCtD
Temsirolimus—Infection—Dactinomycin—muscle cancer	0.000174	0.00215	CcSEcCtD
Temsirolimus—Leukopenia—Vincristine—muscle cancer	0.000172	0.00212	CcSEcCtD
Temsirolimus—Thrombocytopenia—Dactinomycin—muscle cancer	0.000172	0.00212	CcSEcCtD
Temsirolimus—Erythema multiforme—Etoposide—muscle cancer	0.000169	0.00209	CcSEcCtD
Temsirolimus—CYP2D6—head—muscle cancer	0.000169	0.00803	CbGeAlD
Temsirolimus—Rash maculo-papular—Doxorubicin—muscle cancer	0.000168	0.00207	CcSEcCtD
Temsirolimus—Anorexia—Dactinomycin—muscle cancer	0.000167	0.00207	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.000167	0.0105	CbGpPWpGaD
Temsirolimus—Eye disorder—Etoposide—muscle cancer	0.000167	0.00206	CcSEcCtD
Temsirolimus—Bladder pain—Doxorubicin—muscle cancer	0.000167	0.00206	CcSEcCtD
Temsirolimus—Ecchymosis—Doxorubicin—muscle cancer	0.000167	0.00206	CcSEcCtD
Temsirolimus—Mouth ulceration—Doxorubicin—muscle cancer	0.000167	0.00206	CcSEcCtD
Temsirolimus—Convulsion—Vincristine—muscle cancer	0.000166	0.00206	CcSEcCtD
Temsirolimus—Cardiac disorder—Etoposide—muscle cancer	0.000166	0.00205	CcSEcCtD
Temsirolimus—Hypertension—Vincristine—muscle cancer	0.000166	0.00205	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000165	0.0104	CbGpPWpGaD
Temsirolimus—Dermatitis exfoliative—Methotrexate—muscle cancer	0.000164	0.00203	CcSEcCtD
Temsirolimus—Myalgia—Vincristine—muscle cancer	0.000163	0.00202	CcSEcCtD
Temsirolimus—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000163	0.0103	CbGpPWpGaD
Temsirolimus—CYP2D6—testis—muscle cancer	0.000163	0.00775	CbGeAlD
Temsirolimus—Angiopathy—Etoposide—muscle cancer	0.000162	0.002	CcSEcCtD
Temsirolimus—Immune system disorder—Etoposide—muscle cancer	0.000161	0.00199	CcSEcCtD
Temsirolimus—Mediastinal disorder—Etoposide—muscle cancer	0.000161	0.00199	CcSEcCtD
Temsirolimus—Chills—Etoposide—muscle cancer	0.00016	0.00198	CcSEcCtD
Temsirolimus—Sepsis—Doxorubicin—muscle cancer	0.00016	0.00198	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00016	0.00197	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—FOXO4—muscle cancer	0.000158	0.00995	CbGpPWpGaD
Temsirolimus—Oedema—Vincristine—muscle cancer	0.000157	0.00194	CcSEcCtD
Temsirolimus—Anaphylactic shock—Vincristine—muscle cancer	0.000157	0.00194	CcSEcCtD
Temsirolimus—Infection—Vincristine—muscle cancer	0.000156	0.00192	CcSEcCtD
Temsirolimus—Thrombophlebitis—Doxorubicin—muscle cancer	0.000155	0.00191	CcSEcCtD
Temsirolimus—MTOR—PI3K/AKT activation—FOXO4—muscle cancer	0.000154	0.00971	CbGpPWpGaD
Temsirolimus—Diabetes mellitus—Doxorubicin—muscle cancer	0.000154	0.0019	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.000154	0.0019	CcSEcCtD
Temsirolimus—Nervous system disorder—Vincristine—muscle cancer	0.000154	0.0019	CcSEcCtD
Temsirolimus—Thrombocytopenia—Vincristine—muscle cancer	0.000153	0.0019	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—FOXO4—muscle cancer	0.000153	0.00963	CbGpPWpGaD
Temsirolimus—Decreased appetite—Dactinomycin—muscle cancer	0.000152	0.00188	CcSEcCtD
Temsirolimus—Dysgeusia—Etoposide—muscle cancer	0.000152	0.00188	CcSEcCtD
Temsirolimus—Fatigue—Dactinomycin—muscle cancer	0.000151	0.00187	CcSEcCtD
Temsirolimus—Back pain—Etoposide—muscle cancer	0.00015	0.00186	CcSEcCtD
Temsirolimus—Pain—Dactinomycin—muscle cancer	0.00015	0.00185	CcSEcCtD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO4—muscle cancer	0.00015	0.00941	CbGpPWpGaD
Temsirolimus—Anorexia—Vincristine—muscle cancer	0.000149	0.00185	CcSEcCtD
Temsirolimus—Eczema—Doxorubicin—muscle cancer	0.000149	0.00184	CcSEcCtD
Temsirolimus—MTOR—Leptin signaling pathway—FOXO1—muscle cancer	0.000145	0.0091	CbGpPWpGaD
Temsirolimus—Anaemia—Etoposide—muscle cancer	0.000144	0.00178	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000143	0.00177	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000143	0.00176	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.000142	0.00175	CcSEcCtD
Temsirolimus—Insomnia—Vincristine—muscle cancer	0.000142	0.00175	CcSEcCtD
Temsirolimus—Dermatitis bullous—Doxorubicin—muscle cancer	0.00014	0.00173	CcSEcCtD
Temsirolimus—Leukopenia—Etoposide—muscle cancer	0.000139	0.00172	CcSEcCtD
Temsirolimus—Abdominal pain—Dactinomycin—muscle cancer	0.000139	0.00171	CcSEcCtD
Temsirolimus—Body temperature increased—Dactinomycin—muscle cancer	0.000139	0.00171	CcSEcCtD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—IGF2—muscle cancer	0.000137	0.00862	CbGpPWpGaD
Temsirolimus—ABCB1—bone marrow—muscle cancer	0.000137	0.00652	CbGeAlD
Temsirolimus—Decreased appetite—Vincristine—muscle cancer	0.000136	0.00168	CcSEcCtD
Temsirolimus—Cough—Etoposide—muscle cancer	0.000136	0.00168	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Vincristine—muscle cancer	0.000135	0.00167	CcSEcCtD
Temsirolimus—Fatigue—Vincristine—muscle cancer	0.000135	0.00167	CcSEcCtD
Temsirolimus—Convulsion—Etoposide—muscle cancer	0.000135	0.00167	CcSEcCtD
Temsirolimus—Hypertension—Etoposide—muscle cancer	0.000134	0.00166	CcSEcCtD
Temsirolimus—Constipation—Vincristine—muscle cancer	0.000134	0.00166	CcSEcCtD
Temsirolimus—Pain—Vincristine—muscle cancer	0.000134	0.00166	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000134	0.00166	CcSEcCtD
Temsirolimus—MTOR—IGF1R signaling cascade—IGF2—muscle cancer	0.000134	0.0084	CbGpPWpGaD
Temsirolimus—Chest pain—Etoposide—muscle cancer	0.000132	0.00164	CcSEcCtD
Temsirolimus—MTOR—CXCR4-mediated signaling events—FOXO1—muscle cancer	0.000132	0.00831	CbGpPWpGaD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000131	0.00163	CcSEcCtD
Temsirolimus—ABCB1—vagina—muscle cancer	0.000131	0.00625	CbGeAlD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO1—muscle cancer	0.00013	0.00816	CbGpPWpGaD
Temsirolimus—Face oedema—Doxorubicin—muscle cancer	0.000129	0.0016	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—muscle cancer	0.000129	0.0016	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Vincristine—muscle cancer	0.000128	0.00158	CcSEcCtD
Temsirolimus—Anaphylactic shock—Etoposide—muscle cancer	0.000127	0.00157	CcSEcCtD
Temsirolimus—Infection—Etoposide—muscle cancer	0.000126	0.00156	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—muscle cancer	0.000126	0.00156	CcSEcCtD
Temsirolimus—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000126	0.00789	CbGpPWpGaD
Temsirolimus—Blood creatinine increased—Doxorubicin—muscle cancer	0.000125	0.00155	CcSEcCtD
Temsirolimus—Neutropenia—Methotrexate—muscle cancer	0.000125	0.00155	CcSEcCtD
Temsirolimus—Dysuria—Methotrexate—muscle cancer	0.000125	0.00155	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—muscle cancer	0.000125	0.00154	CcSEcCtD
Temsirolimus—Thrombocytopenia—Etoposide—muscle cancer	0.000124	0.00154	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000124	0.00154	CcSEcCtD
Temsirolimus—Body temperature increased—Vincristine—muscle cancer	0.000124	0.00153	CcSEcCtD
Temsirolimus—Abdominal pain—Vincristine—muscle cancer	0.000124	0.00153	CcSEcCtD
Temsirolimus—Skin disorder—Etoposide—muscle cancer	0.000123	0.00152	CcSEcCtD
Temsirolimus—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000123	0.00774	CbGpPWpGaD
Temsirolimus—Dry skin—Doxorubicin—muscle cancer	0.000123	0.00152	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—muscle cancer	0.000122	0.00151	CcSEcCtD
Temsirolimus—ABCB1—head—muscle cancer	0.000121	0.00577	CbGeAlD
Temsirolimus—Anorexia—Etoposide—muscle cancer	0.000121	0.0015	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000121	0.00149	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—muscle cancer	0.00012	0.00148	CcSEcCtD
Temsirolimus—Pneumonia—Methotrexate—muscle cancer	0.00012	0.00148	CcSEcCtD
Temsirolimus—Infestation—Methotrexate—muscle cancer	0.000119	0.00147	CcSEcCtD
Temsirolimus—Infestation NOS—Methotrexate—muscle cancer	0.000119	0.00147	CcSEcCtD
Temsirolimus—Depression—Methotrexate—muscle cancer	0.000119	0.00147	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—muscle cancer	0.000119	0.00147	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000118	0.00744	CbGpPWpGaD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000118	0.00146	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000118	0.00146	CcSEcCtD
Temsirolimus—ABCB1—testis—muscle cancer	0.000117	0.00558	CbGeAlD
Temsirolimus—Renal failure—Methotrexate—muscle cancer	0.000117	0.00145	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—FOXO1—muscle cancer	0.000117	0.00735	CbGpPWpGaD
Temsirolimus—Abdominal distension—Doxorubicin—muscle cancer	0.000117	0.00144	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—muscle cancer	0.000116	0.00144	CcSEcCtD
Temsirolimus—Conjunctivitis—Methotrexate—muscle cancer	0.000116	0.00143	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—muscle cancer	0.000116	0.00143	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—muscle cancer	0.000116	0.00143	CcSEcCtD
Temsirolimus—Hypersensitivity—Vincristine—muscle cancer	0.000115	0.00143	CcSEcCtD
Temsirolimus—MTOR—BDNF signaling pathway—CNR1—muscle cancer	0.000114	0.00718	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—FOXO1—muscle cancer	0.000114	0.00717	CbGpPWpGaD
Temsirolimus—Haematuria—Methotrexate—muscle cancer	0.000114	0.0014	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—FOXO1—muscle cancer	0.000113	0.00711	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.000113	0.00711	CbGpPWpGaD
Temsirolimus—Dyspnoea—Etoposide—muscle cancer	0.000113	0.0014	CcSEcCtD
Temsirolimus—MTOR—ErbB Signaling Pathway—MDM2—muscle cancer	0.000113	0.0071	CbGpPWpGaD
Temsirolimus—Somnolence—Etoposide—muscle cancer	0.000113	0.00139	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—muscle cancer	0.000112	0.00139	CcSEcCtD
Temsirolimus—Asthenia—Vincristine—muscle cancer	0.000112	0.00139	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—muscle cancer	0.000111	0.00138	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—FOXO4—muscle cancer	0.000111	0.007	CbGpPWpGaD
Temsirolimus—Bronchitis—Doxorubicin—muscle cancer	0.000111	0.00138	CcSEcCtD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.000111	0.00695	CbGpPWpGaD
Temsirolimus—Rash—Dactinomycin—muscle cancer	0.000111	0.00137	CcSEcCtD
Temsirolimus—Decreased appetite—Etoposide—muscle cancer	0.00011	0.00136	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—muscle cancer	0.00011	0.00135	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—muscle cancer	0.000109	0.00135	CcSEcCtD
Temsirolimus—Pain—Etoposide—muscle cancer	0.000109	0.00134	CcSEcCtD
Temsirolimus—Constipation—Etoposide—muscle cancer	0.000109	0.00134	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—muscle cancer	0.000108	0.00134	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—muscle cancer	0.000108	0.00134	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000108	0.00133	CcSEcCtD
Temsirolimus—Diarrhoea—Vincristine—muscle cancer	0.000107	0.00133	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—muscle cancer	0.000107	0.00132	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—FOXO4—muscle cancer	0.000106	0.00669	CbGpPWpGaD
Temsirolimus—Pharyngitis—Methotrexate—muscle cancer	0.000106	0.00131	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.000106	0.00665	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—FOXO4—muscle cancer	0.000106	0.00665	CbGpPWpGaD
Temsirolimus—Urinary tract disorder—Methotrexate—muscle cancer	0.000106	0.00131	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—FOXO4—muscle cancer	0.000105	0.00662	CbGpPWpGaD
Temsirolimus—Urethral disorder—Methotrexate—muscle cancer	0.000105	0.0013	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—FOXO4—muscle cancer	0.000105	0.00659	CbGpPWpGaD
Temsirolimus—Weight decreased—Doxorubicin—muscle cancer	0.000105	0.00129	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—muscle cancer	0.000104	0.00129	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—muscle cancer	0.000104	0.00129	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—muscle cancer	0.000104	0.00128	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—muscle cancer	0.000104	0.00128	CcSEcCtD
Temsirolimus—FKBP1A—Spinal Cord Injury—PTGS2—muscle cancer	0.000104	0.00651	CbGpPWpGaD
Temsirolimus—Dizziness—Vincristine—muscle cancer	0.000104	0.00128	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.000103	0.00649	CbGpPWpGaD
Temsirolimus—Infestation NOS—Doxorubicin—muscle cancer	0.000103	0.00128	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—muscle cancer	0.000103	0.00128	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000102	0.00126	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—muscle cancer	0.000101	0.00125	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—muscle cancer	0.000101	0.00125	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—muscle cancer	0.000101	0.00124	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—muscle cancer	0.0001	0.00124	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—muscle cancer	0.0001	0.00124	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—muscle cancer	0.0001	0.00124	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—muscle cancer	0.0001	0.00124	CcSEcCtD
Temsirolimus—Eye disorder—Methotrexate—muscle cancer	0.0001	0.00124	CcSEcCtD
Temsirolimus—Vomiting—Vincristine—muscle cancer	9.96e-05	0.00123	CcSEcCtD
Temsirolimus—Cardiac disorder—Methotrexate—muscle cancer	9.93e-05	0.00123	CcSEcCtD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	9.89e-05	0.00621	CbGpPWpGaD
Temsirolimus—Rash—Vincristine—muscle cancer	9.88e-05	0.00122	CcSEcCtD
Temsirolimus—Dermatitis—Vincristine—muscle cancer	9.87e-05	0.00122	CcSEcCtD
Temsirolimus—MTOR—DAP12 interactions—FOXO4—muscle cancer	9.86e-05	0.0062	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—FOXO4—muscle cancer	9.86e-05	0.0062	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	9.86e-05	0.0062	CbGpPWpGaD
Temsirolimus—Haematuria—Doxorubicin—muscle cancer	9.84e-05	0.00122	CcSEcCtD
Temsirolimus—Headache—Vincristine—muscle cancer	9.82e-05	0.00121	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—FOXO4—muscle cancer	9.77e-05	0.00614	CbGpPWpGaD
Temsirolimus—Epistaxis—Doxorubicin—muscle cancer	9.74e-05	0.0012	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—muscle cancer	9.71e-05	0.0012	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—FOXO4—muscle cancer	9.69e-05	0.00609	CbGpPWpGaD
Temsirolimus—Sinusitis—Doxorubicin—muscle cancer	9.68e-05	0.0012	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—muscle cancer	9.67e-05	0.00119	CcSEcCtD
Temsirolimus—MTOR—Signaling by PDGF—FOXO4—muscle cancer	9.64e-05	0.00606	CbGpPWpGaD
Temsirolimus—Mediastinal disorder—Methotrexate—muscle cancer	9.64e-05	0.00119	CcSEcCtD
Temsirolimus—Chills—Methotrexate—muscle cancer	9.6e-05	0.00119	CcSEcCtD
Temsirolimus—Mental disorder—Methotrexate—muscle cancer	9.37e-05	0.00116	CcSEcCtD
Temsirolimus—Hypersensitivity—Etoposide—muscle cancer	9.35e-05	0.00116	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—muscle cancer	9.31e-05	0.00115	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—muscle cancer	9.31e-05	0.00115	CcSEcCtD
Temsirolimus—Nausea—Vincristine—muscle cancer	9.31e-05	0.00115	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—muscle cancer	9.29e-05	0.00115	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—muscle cancer	9.2e-05	0.00114	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—muscle cancer	9.15e-05	0.00113	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—muscle cancer	9.13e-05	0.00113	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—FOXO4—muscle cancer	9.13e-05	0.00574	CbGpPWpGaD
Temsirolimus—Dysgeusia—Methotrexate—muscle cancer	9.12e-05	0.00113	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—muscle cancer	9.11e-05	0.00113	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—muscle cancer	9.1e-05	0.00113	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—muscle cancer	9.08e-05	0.00112	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—muscle cancer	9.01e-05	0.00111	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—muscle cancer	8.98e-05	0.00111	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—KIT—muscle cancer	8.9e-05	0.0056	CbGpPWpGaD
Temsirolimus—Erythema multiforme—Doxorubicin—muscle cancer	8.76e-05	0.00108	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—FOXO1—muscle cancer	8.74e-05	0.00549	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	8.73e-05	0.00549	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—KIT—muscle cancer	8.69e-05	0.00546	CbGpPWpGaD
Temsirolimus—Diarrhoea—Etoposide—muscle cancer	8.68e-05	0.00107	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—muscle cancer	8.66e-05	0.00107	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—KIT—muscle cancer	8.62e-05	0.00542	CbGpPWpGaD
Temsirolimus—Anaemia—Methotrexate—muscle cancer	8.61e-05	0.00106	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—muscle cancer	8.6e-05	0.00106	CcSEcCtD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	8.43e-05	0.0053	CbGpPWpGaD
Temsirolimus—Angiopathy—Doxorubicin—muscle cancer	8.41e-05	0.00104	CcSEcCtD
Temsirolimus—Dizziness—Etoposide—muscle cancer	8.39e-05	0.00104	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—muscle cancer	8.37e-05	0.00103	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	8.36e-05	0.00525	CbGpPWpGaD
Temsirolimus—Mediastinal disorder—Doxorubicin—muscle cancer	8.35e-05	0.00103	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—muscle cancer	8.34e-05	0.00103	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—muscle cancer	8.31e-05	0.00103	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	8.27e-05	0.0052	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—FOXO1—muscle cancer	8.23e-05	0.00517	CbGpPWpGaD
Temsirolimus—Cough—Methotrexate—muscle cancer	8.13e-05	0.001	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—muscle cancer	8.12e-05	0.001	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—muscle cancer	8.07e-05	0.000998	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—muscle cancer	8.07e-05	0.000998	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—muscle cancer	8.07e-05	0.000997	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—muscle cancer	8.07e-05	0.000997	CcSEcCtD
Temsirolimus—Rash—Etoposide—muscle cancer	8e-05	0.000989	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—muscle cancer	7.99e-05	0.000988	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—HMGA1—muscle cancer	7.98e-05	0.00502	CbGpPWpGaD
Temsirolimus—Headache—Etoposide—muscle cancer	7.95e-05	0.000983	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—muscle cancer	7.93e-05	0.00098	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—muscle cancer	7.93e-05	0.00098	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—muscle cancer	7.93e-05	0.00098	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—muscle cancer	7.9e-05	0.000976	CcSEcCtD
Temsirolimus—MTOR—Insulin Signaling—FOXO1—muscle cancer	7.9e-05	0.00496	CbGpPWpGaD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	7.88e-05	0.000974	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—FOXO1—muscle cancer	7.86e-05	0.00494	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	7.82e-05	0.00491	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—FOXO1—muscle cancer	7.82e-05	0.00491	CbGpPWpGaD
Temsirolimus—Back pain—Doxorubicin—muscle cancer	7.8e-05	0.000964	CcSEcCtD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	7.79e-05	0.00489	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—FOXO1—muscle cancer	7.78e-05	0.00489	CbGpPWpGaD
Temsirolimus—MTOR—LKB1 signaling events—TP53—muscle cancer	7.78e-05	0.00489	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—FOXO1—muscle cancer	7.74e-05	0.00487	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	7.63e-05	0.0048	CbGpPWpGaD
Temsirolimus—Anaphylactic shock—Methotrexate—muscle cancer	7.6e-05	0.00094	CcSEcCtD
Temsirolimus—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	7.59e-05	0.00477	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KIDINS220—muscle cancer	7.58e-05	0.00476	CbGpPWpGaD
Temsirolimus—Infection—Methotrexate—muscle cancer	7.55e-05	0.000934	CcSEcCtD
Temsirolimus—Nausea—Etoposide—muscle cancer	7.54e-05	0.000932	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—muscle cancer	7.46e-05	0.000922	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—muscle cancer	7.45e-05	0.000922	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—muscle cancer	7.44e-05	0.00092	CcSEcCtD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	7.4e-05	0.00465	CbGpPWpGaD
Temsirolimus—Skin disorder—Methotrexate—muscle cancer	7.38e-05	0.000913	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.31e-05	0.0046	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	7.28e-05	0.00458	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—FOXO1—muscle cancer	7.28e-05	0.00458	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—FOXO1—muscle cancer	7.28e-05	0.00458	CbGpPWpGaD
Temsirolimus—Anorexia—Methotrexate—muscle cancer	7.25e-05	0.000896	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—muscle cancer	7.22e-05	0.000892	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—FOXO1—muscle cancer	7.22e-05	0.00454	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	7.15e-05	0.0045	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—FOXO1—muscle cancer	7.12e-05	0.00448	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	7.05e-05	0.00443	CbGpPWpGaD
Temsirolimus—Cough—Doxorubicin—muscle cancer	7.04e-05	0.00087	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—MDM2—muscle cancer	7.01e-05	0.00441	CbGpPWpGaD
Temsirolimus—Convulsion—Doxorubicin—muscle cancer	6.99e-05	0.000864	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—muscle cancer	6.96e-05	0.000861	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.93e-05	0.000856	CcSEcCtD
Temsirolimus—Insomnia—Methotrexate—muscle cancer	6.88e-05	0.00085	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—muscle cancer	6.87e-05	0.000849	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—muscle cancer	6.87e-05	0.000849	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—muscle cancer	6.87e-05	0.000849	CcSEcCtD
Temsirolimus—MTOR—PI3K/AKT activation—MDM2—muscle cancer	6.85e-05	0.0043	CbGpPWpGaD
Temsirolimus—Anxiety—Doxorubicin—muscle cancer	6.84e-05	0.000846	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	6.84e-05	0.0043	CbGpPWpGaD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	6.82e-05	0.000843	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—MDM2—muscle cancer	6.79e-05	0.00427	CbGpPWpGaD
Temsirolimus—Dyspnoea—Methotrexate—muscle cancer	6.78e-05	0.000838	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—muscle cancer	6.76e-05	0.000835	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—FOXO1—muscle cancer	6.74e-05	0.00424	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—FOXO4—muscle cancer	6.72e-05	0.00422	CbGpPWpGaD
Temsirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	6.67e-05	0.0042	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KIT—muscle cancer	6.66e-05	0.00418	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	6.64e-05	0.00417	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—muscle cancer	6.64e-05	0.00417	CbGpPWpGaD
Temsirolimus—Decreased appetite—Methotrexate—muscle cancer	6.61e-05	0.000817	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—muscle cancer	6.58e-05	0.000814	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—muscle cancer	6.58e-05	0.000814	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—muscle cancer	6.56e-05	0.000811	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—muscle cancer	6.55e-05	0.00081	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—muscle cancer	6.54e-05	0.000808	CcSEcCtD
Temsirolimus—Pain—Methotrexate—muscle cancer	6.5e-05	0.000804	CcSEcCtD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—muscle cancer	6.48e-05	0.00407	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Doxorubicin—muscle cancer	6.46e-05	0.000798	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	6.45e-05	0.00405	CbGpPWpGaD
Temsirolimus—Thrombocytopenia—Doxorubicin—muscle cancer	6.45e-05	0.000797	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—muscle cancer	6.39e-05	0.00079	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KIT—muscle cancer	6.37e-05	0.004	CbGpPWpGaD
Temsirolimus—Anorexia—Doxorubicin—muscle cancer	6.27e-05	0.000776	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—KIT—muscle cancer	6.27e-05	0.00394	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Methotrexate—muscle cancer	6.22e-05	0.000768	CcSEcCtD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—muscle cancer	6.17e-05	0.00388	CbGpPWpGaD
Temsirolimus—Abdominal pain—Methotrexate—muscle cancer	6.01e-05	0.000743	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—muscle cancer	6.01e-05	0.000743	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6e-05	0.000741	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—KIT—muscle cancer	5.99e-05	0.00376	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KIT—muscle cancer	5.96e-05	0.00374	CbGpPWpGaD
Temsirolimus—Insomnia—Doxorubicin—muscle cancer	5.95e-05	0.000736	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—KIT—muscle cancer	5.93e-05	0.00373	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KIT—muscle cancer	5.9e-05	0.00371	CbGpPWpGaD
Temsirolimus—Dyspnoea—Doxorubicin—muscle cancer	5.87e-05	0.000725	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—muscle cancer	5.85e-05	0.000723	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	5.81e-05	0.00365	CbGpPWpGaD
Temsirolimus—Decreased appetite—Doxorubicin—muscle cancer	5.72e-05	0.000707	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.68e-05	0.000703	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—muscle cancer	5.68e-05	0.000702	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—muscle cancer	5.63e-05	0.000696	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—muscle cancer	5.63e-05	0.000696	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—muscle cancer	5.6e-05	0.000692	CcSEcCtD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—muscle cancer	5.59e-05	0.00351	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.55e-05	0.00349	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KIT—muscle cancer	5.55e-05	0.00349	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KIT—muscle cancer	5.55e-05	0.00349	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	5.55e-05	0.00349	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—KIT—muscle cancer	5.5e-05	0.00346	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	5.46e-05	0.00343	CbGpPWpGaD
Temsirolimus—Asthenia—Methotrexate—muscle cancer	5.45e-05	0.000674	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KIT—muscle cancer	5.45e-05	0.00343	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KIT—muscle cancer	5.43e-05	0.00341	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD34—muscle cancer	5.41e-05	0.0034	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Doxorubicin—muscle cancer	5.38e-05	0.000665	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—muscle cancer	5.38e-05	0.000665	CcSEcCtD
Temsirolimus—MTOR—AMPK Signaling—TP53—muscle cancer	5.33e-05	0.00335	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—MDM2—muscle cancer	5.24e-05	0.0033	CbGpPWpGaD
Temsirolimus—Body temperature increased—Doxorubicin—muscle cancer	5.2e-05	0.000643	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—muscle cancer	5.2e-05	0.000643	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—muscle cancer	5.2e-05	0.000643	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—KIT—muscle cancer	5.14e-05	0.00323	CbGpPWpGaD
Temsirolimus—Dizziness—Methotrexate—muscle cancer	5.03e-05	0.000621	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—MDM2—muscle cancer	5.02e-05	0.00315	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	4.96e-05	0.00312	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	4.96e-05	0.00312	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—FOXO1—muscle cancer	4.96e-05	0.00312	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—MDM2—muscle cancer	4.94e-05	0.0031	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	4.91e-05	0.00309	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Doxorubicin—muscle cancer	4.85e-05	0.0006	CcSEcCtD
Temsirolimus—Vomiting—Methotrexate—muscle cancer	4.83e-05	0.000598	CcSEcCtD
Temsirolimus—Rash—Methotrexate—muscle cancer	4.79e-05	0.000593	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—muscle cancer	4.79e-05	0.000592	CcSEcCtD
Temsirolimus—Headache—Methotrexate—muscle cancer	4.76e-05	0.000589	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—muscle cancer	4.72e-05	0.000584	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—MDM2—muscle cancer	4.71e-05	0.00296	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—MDM2—muscle cancer	4.69e-05	0.00295	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—VEGFA—muscle cancer	4.69e-05	0.00295	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—MDM2—muscle cancer	4.67e-05	0.00293	CbGpPWpGaD
Temsirolimus—Pruritus—Doxorubicin—muscle cancer	4.66e-05	0.000576	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—MDM2—muscle cancer	4.65e-05	0.00292	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	4.58e-05	0.00288	CbGpPWpGaD
Temsirolimus—Nausea—Methotrexate—muscle cancer	4.52e-05	0.000558	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—muscle cancer	4.5e-05	0.000557	CcSEcCtD
Temsirolimus—FKBP1A—Disease—ENO2—muscle cancer	4.49e-05	0.00282	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—MDM2—muscle cancer	4.37e-05	0.00275	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	4.37e-05	0.00275	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—MDM2—muscle cancer	4.37e-05	0.00275	CbGpPWpGaD
Temsirolimus—Dizziness—Doxorubicin—muscle cancer	4.35e-05	0.000538	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—MDM2—muscle cancer	4.33e-05	0.00272	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—MDM2—muscle cancer	4.29e-05	0.0027	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—MDM2—muscle cancer	4.27e-05	0.00269	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIDINS220—muscle cancer	4.26e-05	0.00268	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.2e-05	0.00264	CbGpPWpGaD
Temsirolimus—Vomiting—Doxorubicin—muscle cancer	4.19e-05	0.000517	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—muscle cancer	4.15e-05	0.000513	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—muscle cancer	4.15e-05	0.000513	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—muscle cancer	4.12e-05	0.00051	CcSEcCtD
Temsirolimus—FKBP1A—Disease—HMGA1—muscle cancer	4.08e-05	0.00257	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—MDM2—muscle cancer	4.04e-05	0.00254	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.99e-05	0.00251	CbGpPWpGaD
Temsirolimus—Nausea—Doxorubicin—muscle cancer	3.91e-05	0.000483	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	3.87e-05	0.00243	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—FOXO4—muscle cancer	3.83e-05	0.00241	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—muscle cancer	3.81e-05	0.00239	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KIT—muscle cancer	3.78e-05	0.00238	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	3.77e-05	0.00237	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FOXO4—muscle cancer	3.68e-05	0.00231	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FOXO4—muscle cancer	3.66e-05	0.0023	CbGpPWpGaD
Temsirolimus—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	3.41e-05	0.00214	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD34—muscle cancer	3.28e-05	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—CDKN2A—muscle cancer	3.27e-05	0.00206	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—FH—muscle cancer	3.24e-05	0.00204	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—MDM2—muscle cancer	3.17e-05	0.002	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	3.15e-05	0.00198	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTCH1—muscle cancer	2.98e-05	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—MDM2—muscle cancer	2.98e-05	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—muscle cancer	2.85e-05	0.00179	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—FOXO1—muscle cancer	2.83e-05	0.00178	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—VEGFA—muscle cancer	2.72e-05	0.00171	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FOXO1—muscle cancer	2.72e-05	0.00171	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FOXO1—muscle cancer	2.71e-05	0.0017	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FOXO4—muscle cancer	2.57e-05	0.00161	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ENO2—muscle cancer	2.53e-05	0.00159	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CNR1—muscle cancer	2.52e-05	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—VEGFA—muscle cancer	2.41e-05	0.00152	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—FH—muscle cancer	2.34e-05	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HMGA1—muscle cancer	2.3e-05	0.00144	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FOXO4—muscle cancer	2.23e-05	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KIT—muscle cancer	2.16e-05	0.00136	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KIT—muscle cancer	2.07e-05	0.0013	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KIT—muscle cancer	2.06e-05	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FOXO4—muscle cancer	2.06e-05	0.0013	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IGF2—muscle cancer	2.06e-05	0.00129	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FOXO1—muscle cancer	1.89e-05	0.00119	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—MED12—muscle cancer	1.83e-05	0.00115	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—muscle cancer	1.82e-05	0.00114	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.77e-05	0.00111	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—FH—muscle cancer	1.77e-05	0.00111	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.71e-05	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MDM2—muscle cancer	1.7e-05	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTCH1—muscle cancer	1.68e-05	0.00105	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO2—muscle cancer	1.67e-05	0.00105	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—FH—muscle cancer	1.67e-05	0.00105	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FOXO1—muscle cancer	1.65e-05	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—MDM2—muscle cancer	1.63e-05	0.00102	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MDM2—muscle cancer	1.62e-05	0.00102	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—muscle cancer	1.57e-05	0.000984	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FOXO1—muscle cancer	1.52e-05	0.000956	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KIT—muscle cancer	1.44e-05	0.000907	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FOXO4—muscle cancer	1.44e-05	0.000907	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CNR1—muscle cancer	1.42e-05	0.00089	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.34e-05	0.000845	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—MED12—muscle cancer	1.32e-05	0.000833	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KIT—muscle cancer	1.26e-05	0.000789	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO2—muscle cancer	1.21e-05	0.000759	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KIT—muscle cancer	1.16e-05	0.000729	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF2—muscle cancer	1.16e-05	0.000728	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MDM2—muscle cancer	1.14e-05	0.000715	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—FH—muscle cancer	1.09e-05	0.000685	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FOXO1—muscle cancer	1.07e-05	0.00067	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.02e-05	0.000638	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MED12—muscle cancer	1e-05	0.000628	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MDM2—muscle cancer	9.89e-06	0.000622	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MED12—muscle cancer	9.42e-06	0.000592	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MDM2—muscle cancer	9.13e-06	0.000574	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—muscle cancer	9.11e-06	0.000573	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—muscle cancer	8.8e-06	0.000553	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—muscle cancer	8.63e-06	0.000543	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—muscle cancer	8.59e-06	0.00054	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—muscle cancer	8.12e-06	0.00051	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—muscle cancer	6.52e-06	0.00041	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MDM2—muscle cancer	6.39e-06	0.000402	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MED12—muscle cancer	6.16e-06	0.000387	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—muscle cancer	5.82e-06	0.000366	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—muscle cancer	5.61e-06	0.000353	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—muscle cancer	4.86e-06	0.000305	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—muscle cancer	4.21e-06	0.000264	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—muscle cancer	3.67e-06	0.000231	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—muscle cancer	3.17e-06	0.000199	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—muscle cancer	2.99e-06	0.000188	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—muscle cancer	1.96e-06	0.000123	CbGpPWpGaD
